BrachyBytes Editorial Advisory Board
Robert Kuske, M.D.
Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D. Catheryn Yashar, M.D.
Vic Zannis, M.D.
ABS Breast Brachytherapy School
Las Vegas, NV
San Antonio Breast Cancer Symposium
December 10-14, 2013
Henry B. Gonzalez Convention Center
San Antonio, TX
|Become a Center of Excellence in APBI
Learn about becoming a Center of Excellence and find ways to grow your APBI program by reaching out to referring physicians and women in the community.
10-Year APBI Data: Equivalent Outcomes, Better Cosmesis
Robert Hong, MD
As acceptance of accelerated partial breast irradiation (APBI) continues to grow, so does the body of evidence supporting its equivalence to whole breast irradiation (WBI).
Most recently, researchers from Hungary published 10-year data from a randomized clinical trial comparing the outcomes of breast conservation therapy (BCT) with APBI versus conventional WBI. Not only did the researchers observe no adverse effect on local control or survival, but they also reported significantly better cosmetic results with the use of APBI.
Radiation oncologist Robert Hong, MD, of Virginia Hospital Center in Arlington, Va., discusses the results of the Hungarian trial, how it compares to his own clinical experience with APBI, and what the data means for the future of early-stage breast cancer treatment.
Literature Review: APBI vs. WBI
Researchers continue to add to the growing literature comparing the efficacy and long-term clinical outcomes of patients treated with APBI vs. WBI, including:
Polgar C, et al.
National Institute of Oncology, Budapest, Hungary
Radiother Oncol (2013)
Wobb J, et al.
Beaumont Cancer Institute, Royal Oak, MI
Presented at 2013 Breast Cancer Symposium
Shah C, et al.
William Beaumont Hospital, Royal Oak, MI
Radiother Oncol (2011)
Studies Show Excellent Outcomes with SAVI
Several studies presented at medical conferences this month showed excellent outcomes with the SAVI® breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival. The data came from the SAVI Collaborative Research Group (SCRG), which was established to study the long-term outcomes of women receiving APBI with SAVI. Read more
- At the Breast Cancer Symposium, researchers presented the largest reported series to date of of DCIS patients treated with SAVI. With 284 patients and more than 2 years of follow-up, researchers noted excellent local control (1.4% recurrence rate) and low toxicity. View poster
At the 55th annual ASTRO meeting:
- A study of 101 patients detailed outcomes with the most mature follow-up of patients treated with SAVI (4.5 years), reporting very low toxicity rates (< 3%) and excellent local control (98%). Overall and cause-specific actuarial survival rates were 100%. View poster
- A study of 576 patients with a median follow-up of 3 years showed similarly low toxicities and a local recurrence rate of less than 2.5%. Overall and cause-specific actuarial survival rates were 99.5%. View poster
- A third study analyzed the radiation treatment plans for over 1,000 patients. The data demonstrated SAVI’s flexibility in shaping the radiation dose, which researchers concluded protects critical structures and makes brachytherapy an option for patients who would not be candidates for other single-entry devices. View poster